Every material Form 8-K Steris filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
STERIS reported fiscal 2026 second-quarter results for the quarter ended September 30, 2025, with revenue from continuing operations up 10% to $1.5 billion and diluted EPS from continuing operations rising to $1.94 from $1.51 a year earlier. The company raised its fiscal 2026 adjusted EPS outlook to $10.15 to $10.30 and its free cash flow expectation to about $850 million, which points to higher expected per-share earnings and cash generation for shareholders.
Q2 revenue from continuing operations rose to $1,460.3 million from $1,328.9 million; constant currency organic growth was 9%.
Diluted EPS from continuing operations was $1.94 vs. $1.51; adjusted EPS was $2.47 vs. $2.14.
Fiscal 2026 adjusted EPS outlook raised to $10.15 to $10.30 from $9.90 to $10.15; free cash flow expected at about $850 million vs. $820 million prior.
Tariffs are estimated to reduce pre-tax profit by about $45 million, unchanged from prior outlook.
STERIS reported first-quarter fiscal 2026 revenue of $1.4 billion, up 9%, and diluted EPS from continuing operations of $1.79, up from $1.41 a year earlier. The company raised its fiscal 2026 reported revenue growth outlook to 8-9% from 6-7%, while its adjusted EPS outlook of $9.90 to $10.15 was unchanged, and CFO Michael J. Tokich is stepping down with Karen Burton taking over on August 18, 2025.
Q1 fiscal 2026 revenue was $1.4 billion, up 9% from $1.3 billion; diluted EPS from continuing operations was $1.79 versus $1.41, and adjusted EPS was $2.34 versus $2.03.
Fiscal 2026 reported revenue growth outlook raised to 8-9% from 6-7%, mainly due to about 200 basis points of expected favorable currency impact.
Adjusted EPS outlook unchanged at $9.90 to $10.15; estimated tariff impact on pre-tax profit increased to about $45 million from $30 million.
CFO Michael J. Tokich steps down; Karen Burton, currently Vice President and Chief Accounting Officer, becomes Senior Vice President and CFO effective August 18, 2025.
STERIS plc said director Dr. Richard Steeves will retire from its Board of Directors at the Annual Meeting of Shareholders on July 31, 2025, and will not stand for re-election. The company said his decision was not the result of any disagreement with the company on strategy, operations, policies or practices.
Dr. Richard Steeves notified the company on July 1, 2025 of his retirement from the Board
Retirement takes effect on the date of the Annual Meeting, scheduled for July 31, 2025
Steeves served 10 years as a Director, according to the company
STERIS reported fiscal 2025 full-year revenue from continuing operations up 6% to $5.5 billion and diluted EPS from continuing operations of $6.16, up from $5.55. Fourth-quarter as reported diluted EPS slipped to $1.48 from $1.54 after a $48.2 million Illinois EO litigation settlement charge. The company also gave fiscal 2026 guidance of 6-7% revenue growth and adjusted EPS of $9.90 to $10.15.
Q4 fiscal 2025 revenue rose 4% to $1.5 billion; as reported diluted EPS was $1.48 versus $1.54 a year earlier
Full-year adjusted diluted EPS was $9.22, up from $8.20 in fiscal 2024
Fiscal 2026 outlook: revenue up 6-7% and adjusted EPS of $9.90 to $10.15, with tariffs estimated to reduce pre-tax profit by about $30 million
Free cash flow for fiscal 2025 was $787.2 million, up from $620.3 million
STERIS reported fiscal 2025 third-quarter results for the quarter ended December 31, 2024, with revenue up 6% to $1.4 billion and diluted EPS from continuing operations of $1.75, up from $1.49 a year earlier. The company lowered its fiscal 2025 revenue growth expectation to about 6% from 6.5% to 7.5% and narrowed its adjusted EPS range to $9.05 to $9.15 from $9.05 to $9.25, mainly due to currency. Shareholders get stronger quarterly growth alongside a less optimistic full-year outlook.
Q3 revenue rose 6% to $1.4 billion; diluted EPS from continuing operations was $1.75 versus $1.49
Adjusted diluted EPS was $2.32 versus $2.09 in the prior-year quarter
Fiscal 2025 revenue growth now expected at about 6%, versus prior expectations of 6.5% to 7.5%
Fiscal 2025 adjusted EPS now $9.05 to $9.15, versus $9.05 to $9.25; company cites about a ten cent negative currency impact
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Steris filing is on SEC EDGAR ↗. 8-K briefs of other companies →